- Home
- OBE vs ADCT Comparison
OBE vs ADCT Comparison
Compare OBE & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBE
- ADCT
- Stock Information
- Founded
- OBE 1979
- ADCT 2011
- Country
- OBE Canada
- ADCT Switzerland
- Employees
- OBE N/A
- ADCT N/A
- Industry
- OBE Oil & Gas Production
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- OBE Energy
- ADCT Health Care
- Exchange
- OBE Nasdaq
- ADCT Nasdaq
- Market Cap
- OBE 391.9M
- ADCT 398.2M
- IPO Year
- OBE N/A
- ADCT 2020
- Fundamental
- Price
- OBE $6.01
- ADCT $3.31
- Analyst Decision
- OBE Buy
- ADCT Strong Buy
- Analyst Count
- OBE 2
- ADCT 6
- Target Price
- OBE $11.50
- ADCT $7.80
- AVG Volume (30 Days)
- OBE 236.1K
- ADCT 641.6K
- Earning Date
- OBE 10-30-2025
- ADCT 11-06-2025
- Dividend Yield
- OBE N/A
- ADCT N/A
- EPS Growth
- OBE N/A
- ADCT N/A
- EPS
- OBE N/A
- ADCT N/A
- Revenue
- OBE $508,849,882.00
- ADCT $77,246,000.00
- Revenue This Year
- OBE N/A
- ADCT $12.71
- Revenue Next Year
- OBE N/A
- ADCT $6.59
- P/E Ratio
- OBE N/A
- ADCT N/A
- Revenue Growth
- OBE 1.49
- ADCT 15.73
- 52 Week Low
- OBE $3.88
- ADCT $1.05
- 52 Week High
- OBE $6.53
- ADCT $3.97
- Technical
- Relative Strength Index (RSI)
- OBE 52.32
- ADCT 54.71
- Support Level
- OBE $5.87
- ADCT $3.20
- Resistance Level
- OBE $6.25
- ADCT $3.38
- Average True Range (ATR)
- OBE 0.20
- ADCT 0.17
- MACD
- OBE -0.01
- ADCT 0.00
- Stochastic Oscillator
- OBE 39.00
- ADCT 49.09
About OBE Obsidian Energy Ltd.
Obsidian Energy Ltd is an intermediate-sized oil and gas producer with strategic assets in Alberta. It operates in a single reporting segment that is exploration, development, and holding an interest in oil and natural gas properties and related production infrastructure in the Western Canada Sedimentary Basin. The company generates the majority of the revenue from the Crude oil sale.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).